JP2012505241A - アルツハイマー病の治療用組成物 - Google Patents
アルツハイマー病の治療用組成物 Download PDFInfo
- Publication number
- JP2012505241A JP2012505241A JP2011531201A JP2011531201A JP2012505241A JP 2012505241 A JP2012505241 A JP 2012505241A JP 2011531201 A JP2011531201 A JP 2011531201A JP 2011531201 A JP2011531201 A JP 2011531201A JP 2012505241 A JP2012505241 A JP 2012505241A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- aryl
- formula
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 **(CNC1)C1C(C1N*)C2=CC1=C*2 Chemical compound **(CNC1)C1C(C1N*)C2=CC1=C*2 0.000 description 17
- WWXOTKXDYPYKEZ-VMYWCARFSA-N CC(C)CN(CCNC1[C@H](C(Cc2ccccc2)NC(c2cccc(C(N(CCC3)C3c3nc(C)c[s]3)=O)c2)=O)O)C1=O Chemical compound CC(C)CN(CCNC1[C@H](C(Cc2ccccc2)NC(c2cccc(C(N(CCC3)C3c3nc(C)c[s]3)=O)c2)=O)O)C1=O WWXOTKXDYPYKEZ-VMYWCARFSA-N 0.000 description 1
- LYRNQOFOHINYSX-MHIMNOSHSA-N CC(CN(Cc1ccccc1)C1)N[C@H]1[C@H]([C@H](Cc1ccccc1)NC(c1cc(C(N(CCC2)C2c2nc(C)c[s]2)=O)ccc1)=O)O Chemical compound CC(CN(Cc1ccccc1)C1)N[C@H]1[C@H]([C@H](Cc1ccccc1)NC(c1cc(C(N(CCC2)C2c2nc(C)c[s]2)=O)ccc1)=O)O LYRNQOFOHINYSX-MHIMNOSHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10443408P | 2008-10-10 | 2008-10-10 | |
| US61/104,434 | 2008-10-10 | ||
| US17562409P | 2009-05-05 | 2009-05-05 | |
| US61/175,624 | 2009-05-05 | ||
| PCT/US2009/060132 WO2010042796A1 (en) | 2008-10-10 | 2009-10-09 | Compounds for treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505241A true JP2012505241A (ja) | 2012-03-01 |
| JP2012505241A5 JP2012505241A5 (https=) | 2012-11-22 |
Family
ID=42100967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531201A Withdrawn JP2012505241A (ja) | 2008-10-10 | 2009-10-09 | アルツハイマー病の治療用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8703947B2 (https=) |
| EP (1) | EP2349308A4 (https=) |
| JP (1) | JP2012505241A (https=) |
| CA (1) | CA2740107A1 (https=) |
| WO (1) | WO2010042796A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100059919A (ko) | 2007-09-24 | 2010-06-04 | 코멘티스, 인코포레이티드 | 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물 |
| US20120214802A1 (en) * | 2009-03-25 | 2012-08-23 | Bilcer Geoffrey M | Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
| WO2013148130A1 (en) * | 2012-03-29 | 2013-10-03 | Oklahoma Medical Research Foundation | Inhibition of memapsin 1 cleavage in the treatment of diabetes |
| US10085969B1 (en) * | 2016-02-12 | 2018-10-02 | University Of South Florida | Sortilin binding compounds, formulations, and uses thereof |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3847770A (en) | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| US4687610A (en) | 1986-04-30 | 1987-08-18 | E. I. Du Pont De Neumours And Company | Low crystallinity polyester yarn produced at ultra high spinning speeds |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| WO1994011706A1 (fr) * | 1992-11-17 | 1994-05-26 | Citizen Watch Co., Ltd. | Circuit detecteur de velocite angulaire |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| NZ533107A (en) | 2001-11-08 | 2007-04-27 | Upjohn Co | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| BR0214736A (pt) | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
| CA2505098A1 (en) * | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| CN100430377C (zh) | 2003-06-30 | 2008-11-05 | 麦克公司 | 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂 |
| ES2323068T3 (es) | 2003-08-08 | 2009-07-06 | Schering Corporation | Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida. |
| US7585885B2 (en) * | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| US8436006B2 (en) | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| WO2006099352A1 (en) * | 2005-03-10 | 2006-09-21 | Bristol-Myers Squibb Company | Novel isophthalates as beta-secretase inhibitors |
| CA2603404A1 (en) | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| AU2006315817A1 (en) * | 2005-11-16 | 2007-05-24 | Merck & Co., Inc. | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| US7902218B2 (en) * | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| CA2739875A1 (en) * | 2008-10-10 | 2010-04-15 | Comentis, Inc. | Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
| US8394807B2 (en) | 2008-11-20 | 2013-03-12 | Purdue Research Foundation | Quinazoline inhibitors of BACE 1 and methods of using |
| WO2010065861A2 (en) | 2008-12-05 | 2010-06-10 | Purdue Research Foundation | Inhibitors of bace 1 and methods for treating alzheimer's disease |
-
2009
- 2009-10-09 WO PCT/US2009/060132 patent/WO2010042796A1/en not_active Ceased
- 2009-10-09 CA CA2740107A patent/CA2740107A1/en not_active Abandoned
- 2009-10-09 US US13/123,157 patent/US8703947B2/en not_active Expired - Fee Related
- 2009-10-09 EP EP09819930A patent/EP2349308A4/en not_active Withdrawn
- 2009-10-09 JP JP2011531201A patent/JP2012505241A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2349308A1 (en) | 2011-08-03 |
| US20110195978A1 (en) | 2011-08-11 |
| WO2010042796A1 (en) | 2010-04-15 |
| US8703947B2 (en) | 2014-04-22 |
| EP2349308A4 (en) | 2012-09-12 |
| CA2740107A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6081354B2 (ja) | 治療活性組成物およびそれらの使用方法 | |
| RU2697665C1 (ru) | Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их | |
| CA2160444C (en) | Aroyl-piperdine derivatives | |
| KR102662215B1 (ko) | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 | |
| EP2925322B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
| JP7567041B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての新規な構造の化合物およびこれを含む薬剤学的組成物 | |
| JP7130873B2 (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
| JP2023540661A (ja) | ＣＣＲ８阻害剤を使用してＴｒｅｇｓを標的とする方法および組成物 | |
| WO2013138753A1 (en) | Prodrugs of riluzole and their method of use | |
| BRPI0915876B1 (pt) | Composto azol, composição farmacêutica e uso do dito composto para tratamento da dor neuropática | |
| JP2007515404A (ja) | アルツハイマー病治療用のベンジルエーテルおよびベンジルアミノ系β−セクレターゼ阻害薬 | |
| WO2012043891A1 (ja) | 眼疾患処置薬 | |
| JP7642859B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物 | |
| JP2006525990A (ja) | 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物 | |
| JP2012505241A (ja) | アルツハイマー病の治療用組成物 | |
| JP2008535863A (ja) | β−セクレターゼ活性を阻害する化合物およびその使用方法 | |
| WO2019022223A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
| AU2006243393A1 (en) | 3 -mono- and 3 , 5-disubstituted piperidine derivatives as renin inhibitors | |
| JP2019506442A (ja) | 新規なカリウムチャネル阻害剤 | |
| WO2010065861A2 (en) | Inhibitors of bace 1 and methods for treating alzheimer's disease | |
| RU2731618C2 (ru) | Нестероидные модуляторы глюкокортиодидных рецепторов для местной доставки лекарств | |
| WO2016006593A1 (ja) | 新規ベンズオキサジン誘導体及びこれを含有する医薬 | |
| US20090281161A1 (en) | Organic Compounds | |
| AU2007260298A1 (en) | Pyrrolidine compounds as renin inhibitors | |
| JP2009185010A (ja) | グリシントランスポーター阻害剤を含有する医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121005 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121005 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20131216 |